Authorization

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - CTMX

NEW YORK, June 24, 2020 /CNW/ --A Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) and certain of its officers.A  The class action, filed in United States District Court for the Northern District of California, and indexed under 20-cv-03432, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired CytomX securities between May 17, 2018, and May 13, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.If you are a shareholder who purchased CytomX securities during the class period, you have until July 20, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.A  A copy of the Complaint can be obtained at www.pomerantzlaw.com. A  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.comA or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A  [Click here for information about joining the class action]CytomX was founded in 2008 and is headquartered in South San Francisco, California.A  CytomX operates as an oncology-focused biopharmaceutical company in the U.S.A  The Company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer.A  CytomX's lead product candidates in the clinical stage include, among others, CX-072 and CX-2009.CytomX has been evaluating CX-072 in its "PROCLAIM" series clinical program for several years.A  For example, the PROCLAIM-CX-072-001 clinical trial was designed to assess the tolerability and preliminary antitumor activity of multiple doses of CX-072 as a monotherapy or as a combination therapy with ipilimumab (which Bristol-Myers Squibb Company markets under the brand name Yervoy) or vemurafenib (which Roche markets under the brand name Zelboraf) in patients with advanced, unresectable solid tumors or lymphoma.A  The Company also began conducting a Phase 2 clinical trial called PROCLAIM-CX-072-002, which was initiated in October 2019 and is an open-label, multi-center clinical trial evaluating CX-072 in combination with ipilimumab in patients with unresectable or metastatic melanoma.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2021    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728